SCHEMBL29680229

SCHEMBL29680229

O=C1CC2(CCCN(c3nc(OCC45CCCN4CCC5)nc4c(F)c(-c5cccc6cccc(F)c56)ncc34)C2)N1

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680240 1.00 KRAS (0.70) KRAS
SCHEMBL24536217 1.00 KRAS (0.70) KRAS
SCHEMBL29680440 0.99 KRAS (0.68) KRAS
SCHEMBL24536321 0.99 KRAS (0.68) KRAS
SCHEMBL29680256 0.94 KRAS (0.72) KRAS
SCHEMBL24536908 0.94 KRAS (0.72) KRAS
SCHEMBL24536502 0.93 KRAS (0.71) KRAS
SCHEMBL29680763 0.93 KRAS (0.71) KRAS
SCHEMBL24536408 0.93 KRAS (0.72) KRAS
SCHEMBL29680122 0.93 KRAS (0.72) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384177-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2024-06-19 — — EP disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
WO-2023018810-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2023-02-16 — — WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
Send feedback